Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2009

View Archived Issues

AEterna Zentaris presents update on phase III study 041 of cetrorelix pamoate in BPH

Natalizumab improves quality of life in Crohn's disease patients

SP-304 well tolerated in phase I study in healthy volunteers

Long-term safety and low-dose efficacy of ropinirole PR studied in Parkinson's disease

Boehringer Ingelheim claims HIV integrase inhibitors for the treatment of HIV infection

Boehringer Ingelheim claims the discovery of novel antimigraine compounds

Long-term and other data on adalimumab in Crohn's disease analyzed

Xanodyne receives FDA approval for Zipsor

CuraGen advances to second stage of enrollment in phase I/II trial of CR011-vcMMAE

MacroGenics and Lilly complete enrollment in phase II/III trial of teplizumab in diabetes

Virax enrolls 50% of participants into South African phase I/IIa trial of VIR-201 HIV vaccine

TGen reports positive results from study of genetic markers in diabetes

Novartis presents novel farnesyl pyrophosphate synthase inhibitors for osteoporosis

FDA Arthritis Advisory Committee sets date to review Auxilium's BLA for Xiaflex

Retreatment with TRU-015 improves rheumatoid arthritis disease activity in phase IIb trial

Paladin launches Twinject Twinpack in Canada for anaphylaxis

Anti-IL-17A antibody AIN-457 induces clinical responses in rheumatoid arthritis patients

Celgene's Revlimid recommended for relapsed/refractory multiple myeloma in the U.K.

Debiopharm and Moffitt Cancer Center sign agreement for Debio-0928

SGN-35 begins phase II trial for anaplastic large cell lymphoma

Clinical hold removed from IMPACT-DCM trial of cardiac repair cells

First European launch for new Blopress Plus strengths

Anti-GM-CSF antibody MT-203 begins first phase I study

Second phase II study for HP-802-247 cell-based wound therapy

Novel angiotensin receptor blocker K-868 active against experimental diabetic nephropathy

OSI Prosidion reports development of dual DPP-IV inhibitor/GPR119 agonist

Meal-related symptoms improved with Z-338 in functional dyspepsia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...